Charlie Garnett-Benson, Executive Director-Translation Medicine Development Portfolio Team Lead at Bristol Myers Squibb, shared a post on LinkedIn:
“AACR26 was a walk down research career memory lane for me. Ran into Andrean Burnett who I served alongside on many NCI study sections while in academia. I was the immunologist brought to the radiation biology grant review panel. Ran into Karuna Mittal, PhD, an amazing PhD student whose dissertation committee I served on once upon a time in academia. Happy to see that she is now thriving in a Dx biotech company. Met up with Heather K. Beasley, Ph.D. who I first met as a BMS supported UNCF EE just fellow.
We’ve stayed in touch, and I’m excited to see where this energetic and talented scientist ends up on the next step in her career journey. Today, I got to talk for a while with the Alan Korman (while sharing translational data from a molecule he brought to life!) and Howard Streicher. I met Dr. Streicher when I was a wee post-doc at the NCI in the LTIB, and was lucky enough to cross paths with Dr. Korman briefly when I first joined BMS. Such a pleasure to chat with these two and pick their brains about what we do and don’t know in immuno-oncology, and where they think we are headed next.
Fun bonus was having a co-worker send over a picture of me with Sandra Demaria, from SITC last year, in a pamphlet they were handing out at the meeting. Of course, I enjoyed lots of interesting scientific sessions and networking. There is no lack of innovation. The synthesis and application is the tough task ahead but I am energized by the possibilities.”
Other articles featuring Charlie Garnett-Benson on OncoDaily.
